| Old Articles: <Older 5341-5350 Newer> |
|---|
 |
The Motley Fool
January 8, 2009
Brian Orelli |
Lowered Guidance? No Problem! Investors with long-term horizons will likely see this downturn as a small blip on the general upward trend of Intuitive Surgical.   |
The Motley Fool
January 7, 2009
Brian Orelli |
A One-Hit Wonder Goes for No. 2 Onyx Pharmaceuticals announces its second license in the last few months. |
The Motley Fool
January 7, 2009
Brian Orelli |
A Free Call Option on a Drug Orphan-drug specialist BioMarin announces that it has licensed Riquent, La Jolla Pharmaceutical's phase 3 lupus nephritis treatment. |
The Motley Fool
January 6, 2009
Brian Orelli |
Boston Scientific Gets Gussied Up Boston Scientific is buying it's current partner, Ireland-based Labcoat. |
The Motley Fool
January 5, 2009
Brian Orelli |
Pfizer Goes Shopping and Water Is Wet: News at 11! In an interview with the Financial Times, Pfizer's CEO Jeff Kindler said the company is willing to buy another company. |
The Motley Fool
December 31, 2008
Brian Orelli |
An Imminent Drug Approval? Really? Lilly may finally hear about prasugrel. |
The Motley Fool
December 31, 2008
Brian Orelli |
Bayer's Little Lost Drug Patent The drugmaker is dusting one off and suing Abbott Labs. |
The Motley Fool
December 31, 2008
Brian Orelli |
Medical Device Makers Are as Cheap as Ever Value investing, health-care style. |
The Motley Fool
December 31, 2008
Brian Orelli |
Health Care's Golden Children The whole industry wasn't down this year. |
The Motley Fool
December 30, 2008
Brian Orelli |
2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers. |
| <Older 5341-5350 Newer> Return to current articles. |
